Research
Hormonal
PPARα agonists (fibrates) lower serum triglycerides and raise HDL cholesterol by directly binding to the PPARα receptor, thereby inducing genes involved in fatty acid oxidation and peroxisome proliferation.
Fibrates are a class of drugs that work by directly activating the PPARα receptor to lower triglycerides and raise HDL. They are most effective when prescribed for specific lipid profiles, though they require higher doses than newer agents and are less selective than PPARγ agonists.
GoodSupportsHIGH confidence
These data provided strong evidence that PPARα mediates the hypolipidemic effects of fibrates and other peroxisome proliferators... These data provide strong evidence that the fibrates and other hypolipidemic agents mediate their therapeutic effects by direct binding to PPARα.
Why this rating
Strong in vitro and in vivo correlation between binding potency and clinical effect, though human physiological response differs from rodents.
Source
Peroxisome Proliferator-Activated Receptors: From Genes to Physiology
Steven A. Kliewer · Recent Progress in Hormone Research · 2001
DOI 10.1210/rp.56.1.239
narrative_reviewCited 426×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- PPARγ agonists (glitazones) improve insulin sensitivity and lower glucose in type 2 diabetes by promoting fatty acid flux into adipose tissue, thereby reducing lipid interference with glucose utilization in muscle and liver.Strong
- PPARs function as metabolic sensors that bind directly to a variety of natural fatty acids and oxidized fatty acid metabolites (eicosanoids), coupling fatty acid flux to the transcriptional regulation of lipid and glucose homeostasis genes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →